This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

SAVINGS DEADLINE EXPIRES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Leendert van ven Bos
Chief Executive Officer at EnzyTag BV
Speaker

Profile

Leendert van den Bos obtained his MSc- and PhD-degree in bio-organic chemistry from Leiden University. He joined Organon BioSciences as a Scientist in 2007 and worked subsequently for Schering-Plough, Merck Sharp & Dohme and Aspen Pharmacare mostly in the field of Process Research & Development. End of 2018, he co-founded EnzyTag and serves as CEO since then. Leendert holds an Executive MBA from Nyenrode University. In 2022, he co-founded the biotech start-up GlycoTheraperutics focusing on developing carbohydrate-based molecules that serve as new checkpoint

Agenda Sessions

  • Fragment-based Approaches for Acylated Peptide Synthesis; An Analysis of Cost and Capacity

    4:15pm